Immodgel is a collaborative research project, started in October 2013. It focuses on local immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages. The main objective of the European project Immodgel is to find innovative solutions to the frequent adverse immune reactions following implantation procedures. For this purpose, the consortium will create a personalised, immunomodulatory system that will be adjustable for any implant, medical device or transplant. It is co-financed by the European Commission with a funding of 5.85 million Euros (EU FP7 Grant Number 602694).
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients.
PROTiP Medical is a French biomedical company that develops innovative solutions in the field Otorhinolaryngology. PROTiP has 2 CE-marked products: 1) NewBreez, an intralaryngeal implant for swallowing disorders; 2) ENTegral, an implant to replace laryngeal functions after total laryngectomy. PROTiP is also active in the fields of hydrogel development for tissue engineering and regeneration and 3D printing of implants and surface treatment and coating technologies.
The Cell and Gene Therapy Catapult (CGT Catapult) was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, CGT Catapult works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. CGT Catapult offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. They aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s “eight great technologies” that support UK science strengths and business capabilities. The Cell and Gene Therapy Catapult works with Innovate UK.